Home One Internist's Glance At MannKind's Afrezza
 

Keywords :   


One Internist's Glance At MannKind's Afrezza

2015-01-03 19:28:42| Biotech - Topix.net

I wanted to offer my assessment of the utility of Afrezza as a clinician, after doing a review of some of the available clinical data and evidence. A small meta-analysis of open-label randomized controlled trials from ClinicalTrials.gov indicates that Afrezza was associated with smaller reductions in A1C than control, and higher discontinuation rates.

Tags: glance afrezza

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
28.09BIO completes transition of Thr Pro 80% to 85% Active
28.09This Week in Agribusiness, September 28, 2024
28.09This Week in Agribusiness, September 28, 2024
28.09Eastern North Pacific Tropical Weather Outlook
28.09Atlantic Tropical Weather Outlook
28.09Weekly Recap: AkzoNobel, BASF, Axalta, PPG Top This Weeks Stories
28.09Post-Tropical Cyclone Helene Graphics
28.09Post-Tropical Cyclone Helene Public Advisory Number 20
More »